Sahithi Pamarthy

Sahithi Pamarthy

Auto-generated profile, based on publicly available information

Sahithi Pamarthy

Department of Microbiology and Immunology, Rosalind Franklin University of Medicine and Science, North Chicago, IL, USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 February 2018 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
SPSahithi Pamarthy
Sahithi Pamarthy
AKArpita Kulshrestha
Arpita Kulshrestha
GKGajendra K. Katara
Gajendra K. Katara
KBKenneth D. Beaman
Kenneth D. Beaman
The Vacuolar ATPase (V-ATPase) is a proton pump responsible for controlling the intracellular and extracellular pH of cells. The structure of V-ATPase has been highly conserved among all eukaryotic cells and is involved in diverse functions across species. V-ATPase is best known for its acidification of endosomes and lysosomes and is also important for luminal acidification of specialized cells. Several reports have suggested the involvement of V-ATPase in maintaining an alkaline intracellular and acidic extracellular pH thereby aiding in proliferation and metastasis of cancer cells respectively. Increased expression of V-ATPase and relocation to the plasma membrane aids in cancer modulates key tumorigenic cell processes like autophagy, Warburg effect, immunomoduation, drug resistance and most importantly cancer cell signaling. In this review, we discuss the direct role of V-ATPase in acidification and indirect regulation of signaling pathways, particularly Notch Signaling.

21 January 2015 in Oncotarget
Verified
Journal Article
Open access
PDF file
AKArpita Kulshrestha
Arpita Kulshrestha
GKGajendra K. Katara
Gajendra K. Katara
SISafaa Ibrahim
Safaa Ibrahim
SPSahithi Pamarthy
Sahithi Pamarthy
MJMukesh K. Jaiswal
Mukesh K. Jaiswal
KBKenneth D. Beaman
Kenneth D. Beaman
Vacuolar ATPase 'a2' isoform exhibits distinct cell surface accumulation and modulates matrix metalloproteinase activity in ovarian cancer Vacuolar ATPase ‘a2’ isoform exhibits distinct cell surface accumulation and modulates matrix metalloproteinase activity in ovarian cancer

1 September 2017 in Critical Reviews in Oncology/Hematology
Verified
Journal Article
Closed access
ZRZachary Z. Reinstein
Zachary Z. Reinstein
SPSahithi Pamarthy
Sahithi Pamarthy
VSVinay Sagar
Vinay Sagar
RCRicardo Costa
Ricardo Costa
SASarki A. Abdulkadir
Sarki A. Abdulkadir
BCBenedito A. Carneiro
Benedito A. Carneiro

12 December 2017 in Molecular Oncology
Verified
Journal Article
Open access
PDF file
GKGajendra K. Katara
Gajendra K. Katara
AKArpita Kulshrestha
Arpita Kulshrestha
LMLiqun Mao
Liqun Mao
XWXin Wang
Xin Wang
MSManoranjan Sahoo
Manoranjan Sahoo
KBKenneth D. Beaman
Kenneth D. Beaman
Extracellular matrix (ECM) critically impacts tumor progression and is influenced by both cancer and host tissue cells. While our understanding of cancer cell ECM remodeling is widespread, the importance of host tissue ECM, which provides initial congenial environment for primary tumor formation, is partly understood. Here, we report a novel role of epithelial cell‐associated vacuolar ATPase ‘a2’ isoform (a2V) in regulating breast tissue ECM stiffness to control metastasis. Using a mammary gland‐specific a2V‐knockout model, we show that in the absence of a2V, breast tumors exhibit atypically soft tumor phenotype, less tumor rigidity, and necrotic tumor microenvironment. These tumors contain a decreased number of cancer cells at primary tumor site, but showed extensive metastases compared to control. Nanomechanical evaluation of normal breast tissues revealed a decrease in stiffness and collagen content in ECM of a2V‐deleted breast tissues. Mechanistically, inhibition of a2V expression caused dispersed Golgi morphology with relocation of glycosyltransferase enzymes to early endosomes in mammary epithelial cells. This resulted in defective glycosylation of ECM proteins and production of compromised ECM that further influenced tumor metastasis. Clinically, in patients with cancer, low a2V expression levels in normal breast tissue correlated with lymph node metastasis. Thus, using a new knockout mouse model, we have identified a2V expression in epithelial cells as a key requirement for proper ECM formation in breast tissue and its expression levels can significantly modulate breast tumor dissemination. Evaluation of a2V expression in normal breast tissues can help in identifying patients with high risk of developing metastases.

14 June 2018 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
BCBenedito A. Carneiro
Benedito A. Carneiro
SPSahithi Pamarthy
Sahithi Pamarthy
ASAmi N. Shah
Ami N. Shah
VSVinay Sagar
Vinay Sagar
KUKenji Unno
Kenji Unno
SASarki A. Abdulkadir
Sarki A. Abdulkadir
Purpose: Small cell carcinoma of the prostate (SCCP) is an aggressive disease that can arise de novo or by transdifferentiation from prostate adenocarcinoma. Alterations in anaplastic lymphoma kinase (ALK) gene are involved in neuroblastoma, lung cancer, and other malignancies, but its role in SCCP has not been documented. We describe a patient with refractory de novo SCCP with ALK F1174C–activating mutation who obtained clinical benefit from treatment with ALK inhibitor. Experimental Design: Next-generation sequencing (NGS) was used to analyze primary and circulating tumor DNA (ctDNA). Prostate cancer databases were queried for alterations in ALK gene, mRNA, and its impact in clinical outcomes. In vitro prostate cell line/organoid models were generated by lentiviral-mediated expression of ALK and ALK F1174C and assessed for response to ALK inhibitors crizotinib and alectinib. Results: NGS analysis of the primary tumor and ctDNA of a 39-year-old patient with refractory SSCP identified ALK F1174C mutation. Treatment with second-generation ALK inhibitor alectinib resulted in radiographic stable disease for over 6 months, symptomatic improvement, and significant molecular response as reflected by declining ctDNA allele fraction. Analysis of prostate cancer datasets showed that ALK amplification was associated with poor outcome. In prostate cancer cells and organoids, ALK F1174C expression enhanced growth and induced expression of the neuroendocrine marker neuron-specific enolase. Alectinib was more effective than crizotinib in inhibiting ALK F1174C–expressing cell growth. Conclusions: These findings implicate ALK-activating mutations in SCCP pathogenesis and suggest the therapeutic potential of targeting ALK molecular alterations in some patients with SCCP. Clin Cancer Res; 24(12); 2732–9. ©2018 AACR.

29 January 2016 in Molecular Oncology
Verified
Journal Article
Closed access
AKArpita Kulshrestha
Arpita Kulshrestha
GKGajendra K. Katara
Gajendra K. Katara
JGJordyn Ginter
Jordyn Ginter
SPSahithi Pamarthy
Sahithi Pamarthy
SISafaa A. Ibrahim
Safaa A. Ibrahim
KBKenneth D. Beaman
Kenneth D. Beaman